Redlen Technologies Announces Appointment of New Board Member and New Vice President of Operations

VICTORIA, BC – JANUARY 16, 2011 – Redlen Technologies announced today that Dr. Edmund F. Becker, JR, PhD, has joined its Board of Directors. Dr. Becker brings more than 40 years of executive and management experience in the high growth OEM medical products industry.

Dr. Becker served as the executive vice president and chief operations officer at Analogic Corporation in Peabody, Massachusetts, from December 2005 to July 2008. Prior to that role, he was vice president/general manager of its OEM Medical Imaging Products Division, responsible for management of the organization that grew to become the largest and most profitable business unit in the Company. During his tenure at Analogic, Dr. Becker played a key role in the profitable growth of the company from $10M to $450M revenues. His extensive academic background includes a B.S. Physics, with General Honors, University of Chicago; Woodrow Wilson Fellowship, University of Chicago, Physics; Fulbright Fellowship, University of Utrecht, Netherlands; NIH Fellowships, University of Chicago, PhD Biophysics; and an NSF Postdoctoral Fellowship, Harvard University.

“Dr Becker’s extensive track record of innovation and commercial success in the medical imaging industry will be a great asset to me as well as to other board members as Redlen emerges as a key sub-system supplier for next generation medical imaging systems,” says Glenn Bindley, president and CEO of Redlen Technologies.

REDLEN WELCOMES VP OPERATIONS TO ITS EXECUTIVE MANAGEMENT TEAM

In addition, Redlen announced that Dr. Graeme Macaloney, P.Eng., PhD, has joined the company as its new vice president of operations. In this role, Dr. Macaloney will oversee the Company’s strategic operations activities, as well as programs and resources to achieve aggressive growth and profitability goals across Redlen’s broad line of CZT solutions.

Dr. Macaloney brings more than 20 years of experience managing advanced manufacturing operations. Most recently, he served as the president of QSV Biologics, a biopharmaceutical contract manufacturing company, where he grew QSV to a global mid-tier contract advanced manufacturing company in the competitive North American market-place and achieved profitability in three years.

Previously he served as the chief operating officer at Pence Inc., University of Alberta where he was responsible for network operations, including an extensive discovery research network. Dr. Macaloney was also the group leader at Eli Lilly and Co., where he revitalized and built their advanced manufacturing process development group in support of de-bottlenecking operations, increasing productivity and reducing costs.

“I am extremely pleased to have Dr. Macaloney join the Redlen executive team to lead our ambitious scale up and growth plan,” says Glenn Bindley, president and CEO of Redlen Technologies. “His background is ideally suited to building the key teams and programs we need to execute our vision.”

Dr Macaloney is a fellow of the Institution of Chemical Engineers, and holds a PhD from Strathclyde University/Alberta Research Council as well as a M.Sc. in Process (Biochemical) Engineering, University College London, and a B.Sc. in Applied Microbiology, Strathclyde University.

ABOUT REDLEN TECHNOLOGIES

Redlen Technologies is a leading manufacturer of high resolution Cadmium Zinc Telluride (CZT) semiconductor radiation detectors which are enabling a new generation of high performance detection and imaging equipment including Nuclear Cardiology, CT Scanning, Baggage Scanning and Dirty Bomb Detection. The company also offers a thin film solar Cadmium Telluride (CdTe) feedstock solution, which delivers volume quantities of high purity, high performance semiconductor material to the Thin Film Solar Photovoltaic (PV) market. For more information on the company and its products, please visit its website www.redlen.com.